Browsing by Subject "Unknown primary"
Now showing items 21-40 of 60
-
Article
Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: Active, but how effective?
(2005)Carcinoma of unknown primary (CUP) is characterized by dismal patient survival. The outcome of patients with two favourable risk CUP subsets was studied. Eighty patients diagnosed with either midline lymph node metastases ...
-
Article
Combination regimen with carboplatin, epirubicin and etoposide in metastatic carcinomas of unknown primary site: A Hellenic Co-operative Oncology Group phase II study
(1998)The encouraging results that have been reported for cisplatin combination chemotherapy in a minority of patients with cancer of unknown primary (CUP) together with the previously shown equal activity of carboplatin in this ...
-
Article
Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: Multiple-treatments meta-analysis
(2009)Objectives: To synthesize the evidence from randomized controlled trials concerning systemic treatment regimens for patients with cancer of unknown primary site (CUP). Data sources: PubMed and the Cochrane Library Central ...
-
Article
Diagnostic and therapeutic management of cancer of an unknown primary
(2003)Metastatic Cancer of Unknown Primary Site (CUP) accounts for approximately 3% of all malignant neoplasms and is therefore one of the 10 most frequent cancer diagnoses in man. Patients with CUP present with metastatic disease ...
-
Article
Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: A multicentre Hellenic Cooperative Oncology Group phase II study
(2008)Introduction. Taxane/platinum combinations exhibit synergistic cytotoxicity and activity against a broad range of solid tumours. We sought to optimise the regimen as a suitable outpatient palliative treatment for cancer ...
-
Article
-
Article
-
Article
Evaluation of six tumor markers in patients with carcinoma of unknown primary
(1994)We have retrospectively evaluated six serum tumor markers in 85 patients with carcinoma of unknown primary. The serum levels of carcinoembryonic antigen (CEA), CA 19‐9, CA 15‐3, CA 125, β‐chorionic gonadotropin (β‐HCG) and ...
-
Article
Exploring the biology of cancer of unknown primary: Breakthroughs and drawbacks
(2013)Background: Cancer of unknown primary (CUP) ranks among the ten most common malignancies worldwide. Cancer of unknown primary presents as disseminated disease, has a dismal prognosis and remains a diagnosis of exclusion. ...
-
Article
Forty years experience of treating cancer of unknown primary
(2007)Cancer of unknown primary site (CUP) is not a rare tumour. It accounts as the seventh to eighth most frequently diagnosed cancer in a general medical oncology service. Since CUP is not a homogeneous disease and it consists ...
-
Article
Global microRNA profiling in favorable prognosis subgroups of cancer of unknown primary (CUP) demonstrates no significant expression differences with metastases of matched known primary tumors
(2013)No data exist on biologic differences between Cancer of unknown primary (CUP) and metastatic solid tumors of known primary site. We assigned a primary tissue of origin in 40 favorable CUP patients (A: serous peritoneal ...
-
Article
Global profiling of EGFR gene mutation, amplification, regulation and tissue protein expression in unknown primary carcinomas: To target or not to target?
(2007)Introduction: Epidermal growth factor receptor (EGFR) signalling contributes to malignant transformation and survival. We studied molecular predictors of benefit from EGFR-modulating therapies in patients with cancer of ...
-
Article
Immunohistochemical study of the epithelial-mesenchymal transition phenotype in cancer of unknown primary: Incidence, correlations and prognostic utility
(2012)Background: The epithelial to mesenchymal transition (EMT) has been associated with metastatic dissemination and poor outcome in several solid tumour types. Our aim was to study its incidence and its prognostic significance ...
-
Article
Insights into the epithelial mesenchymal transition phenotype in cancer of unknown primary from a global microRNA profiling study
(2014)Purpose: We sought to study the microRNA regulation of epithelial mesenchymal transition (EMT), the acquisition of migratory, mesenchymal-like properties of epithelial cells, in cancer of unknown primary (CUP). Patients ...
-
Article
Intracellular signalling via the AKT axis and downstream effectors is active and prognostically significant in cancer of unknown primary (CUP): A study of 100 CUP cases
(2012)Background: Hypothesising that cancer of unknown primary (CUP) may harbour unique characteristics, we present a translational study of the immunohistochemical expression and clinical correlation of key PTEN/AKT pathway ...
-
Article
Liver metastases from cancer of unknown primary (CUPL): A retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature
(2008)Aim: Patients with liver metastases from cancer of unknown primary (CUPL) have a dismal prognosis. We retrospectively analysed their management and outcome and performed a systematic review of CUPL series published in the ...
-
Article
Long-term survivors among patients with cancer of unknown primary
(2012)There is a general conception among oncologists that CUP patients behave poorly to treatment and carry a dismal survival. In this paper we are trying to elucidate the different groups of CUP patients and to describe in ...
-
Article
Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature
(2011)Introduction: Although more than 90% of melanomas have a cutaneous origin, occasionally it is discovered as a secondary deposit without evident primary site. The aim of this study was to systematically review published ...
-
Article
Matrix metalloproteinases in carcinoma of unknown primary
(2005)BACKGROUND. The purpose was to study proteolysis-related molecules, matrix metalloproteinase-2 (MMP-2) and MMP-9 and tissue inhibitor of metalloproteinases-1 (TIMP-1), in carcinoma of unknown primary (CUP). METHODS. ...
-
Article
A mini review on cancer of unknown primary site: A clinical puzzle for the oncologists
(2015)Cancer of unknown primary (CUP) is a well recognized clinical syndrome, accounting for 3-5% of all malignancies. It is characterized as a disease with an early dissemination of metastases without a primary detected site ...